Total Payments
$48,030
2024 Payments
$62.38
Companies
10
Transactions
53
Medicare Patients
1,428
Medicare Billing
$191,040
Payment Breakdown by Category
Other$41,942 (87.3%)
Consulting$3,300 (6.9%)
Food & Beverage$2,118 (4.4%)
Travel$648.00 (1.3%)
Education$22.82 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,942 | 21 | 87.3% |
| Consulting Fee | $3,300 | 1 | 6.9% |
| Food and Beverage | $2,118 | 25 | 4.4% |
| Travel and Lodging | $648.00 | 4 | 1.3% |
| Education | $22.82 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $20,646 | 21 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $12,128 | 12 | $0 (2019) |
| Amgen Inc. | $11,687 | 13 | $0 (2021) |
| ABBVIE INC. | $3,300 | 1 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $83.26 | 1 | $0 (2021) |
| Legend Biotech USA Inc. | $62.38 | 1 | $0 (2024) |
| Janssen Research & Development, LLC | $50.00 | 1 | $0 (2019) |
| Janssen Global Services, LLC | $35.70 | 1 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $25.25 | 1 | $0 (2017) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62.38 | 1 | Legend Biotech USA Inc. ($62.38) |
| 2022 | $3,315 | 2 | ABBVIE INC. ($3,300) |
| 2021 | $6,866 | 6 | Celgene Corporation ($4,363) |
| 2020 | $4,154 | 4 | Celgene Corporation ($3,758) |
| 2019 | $16,563 | 19 | Takeda Pharmaceuticals U.S.A., Inc. ($7,285) |
| 2018 | $11,359 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($4,842) |
| 2017 | $5,711 | 7 | Celgene Corporation ($5,576) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $62.38 | General |
| 03/11/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $15.38 | General |
| 12/14/2021 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $83.26 | General |
| 11/09/2021 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,665.00 | General |
| 10/19/2021 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $97.92 | General |
| 08/17/2021 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| 08/10/2021 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 02/22/2021 | Celgene Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 11/17/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 10/14/2020 | Amgen Inc. | Kyprolis (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $383.00 | General |
| Category: Oncology | ||||||
| 02/19/2020 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,673.00 | General |
| Category: Hematology | ||||||
| 02/19/2020 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | Cash or cash equivalent | $85.44 | General |
| Category: Hematology | ||||||
| 12/18/2019 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| 12/12/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| 12/12/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/11/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $118.29 | General |
| 11/19/2019 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| 10/30/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $55.70 | General |
| 09/26/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| 09/26/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $89.96 | General |
| 09/17/2019 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | In-kind items and services | $370.00 | General |
| Category: Hematology / Oncology | ||||||
| 09/17/2019 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | In-kind items and services | $168.00 | General |
| Category: Hematology / Oncology | ||||||
| 09/17/2019 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | In-kind items and services | $65.00 | General |
| Category: Hematology / Oncology | ||||||
| 09/17/2019 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $45.00 | General |
| Category: Hematology / Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 332 | 611 | $260,063 | $43,855 |
| 2022 | 9 | 354 | 651 | $282,019 | $50,117 |
| 2021 | 8 | 356 | 723 | $283,735 | $55,781 |
| 2020 | 7 | 386 | 775 | $255,850 | $41,287 |
Total Patients
1,428
Total Services
2,760
Medicare Billing
$191,040
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 83 | 224 | $132,384 | $22,487 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 128 | 197 | $53,350 | $8,760 | 16.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 66 | 118 | $49,262 | $8,222 | 16.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 23 | 23 | $15,948 | $2,254 | 14.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 32 | 49 | $9,119 | $2,132 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 78 | 201 | $107,844 | $21,077 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 112 | 172 | $42,190 | $7,882 | 18.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 94 | $51,982 | $7,520 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 71 | $26,809 | $4,985 | 18.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 38 | 53 | $8,745 | $2,492 | 28.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $15,649 | $2,310 | 14.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $17,352 | $1,899 | 10.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 11 | 11 | $7,232 | $1,161 | 16.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 15 | 17 | $4,216 | $790.17 | 18.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 86 | 228 | $118,773 | $25,943 | 21.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 121 | 210 | $50,253 | $10,221 | 20.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 103 | $55,311 | $8,016 | 14.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 46 | 83 | $30,633 | $5,810 | 19.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 24 | 42 | $6,930 | $2,139 | 30.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 20 | 21 | $10,710 | $1,660 | 15.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 15 | 15 | $9,424 | $1,618 | 17.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 17 | 21 | $1,701 | $373.12 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 124 | 299 | $107,211 | $17,246 | 16.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 119 | $61,999 | $9,834 | 15.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 132 | 225 | $52,355 | $7,523 | 14.4% |
About Dr. Jason Valent, M.D
Dr. Jason Valent, M.D is a Hematology & Oncology healthcare provider based in Strongsville, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013936871.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Valent, M.D has received a total of $48,030 in payments from pharmaceutical and medical device companies, with $62.38 received in 2024. These payments were reported across 53 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($41,942).
As a Medicare-enrolled provider, Valent has provided services to 1,428 Medicare beneficiaries, totaling 2,760 services with total Medicare billing of $191,040. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Strongsville, OH
- Active Since 07/19/2006
- Last Updated 10/14/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013936871
Products in Payments
- Revlimid (Drug) $16,129
- VENCLEXTA (Drug) $3,300
- Kyprolis (Drug) $383.00
- NINLARO (Drug) $113.35
- Kyprolis (Biological) $109.50
- DARZALEX (Drug) $50.00
- DARZALEX (Biological) $35.70
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.